<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596256</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-301</org_study_id>
    <nct_id>NCT02596256</nct_id>
  </id_info>
  <brief_title>Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)</brief_title>
  <official_title>Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial investigated the safety and efficacy of apatinib plus docetaxel, as a treatment
      option for heavily pretreated patients with advanced gastric cancer.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>contrast group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel (60mg/m2, i.v. d1 q21d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>ATAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>contrast group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: more than 18 years old, male or female;

          2. Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the
             gastroesophageal junction) with measurable metastases outside the stomach (measuring ≥
             10mm on spiral computed tomography(CT) scan, satisfying the criteria in Response
             Evaluation Criteria In Solid Tumors (RECIST) 1.1);

          3. Failure of prior therapy (during or after treatment) in patients who have received at
             first line chemotherapy regimens(platinum - based regimens);

          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1;

          5. Major organ function has to meet the following criteria; (1) For results of blood
             routine test and biochemical tests:

               1. Hemoglobin (HB) ≥ 80g / L,

               2. ANC ≥ 1.5 × 109 / L,

               3. PLT ≥ 90 × 109 / L,

               4. ALT and AST ≤ 2.5 × ULN, liver metastases, if any, the ALT and AST≤5 × ULN,

               5. Bilirubin ≤ 1.5 times the upper limit of normal (ULN),

               6. Serum creatinine ≤ 1.5 times the upper limit of normal (ULN),

               7. Serum albumin ≥ 30g / L;

          6. An expected survival of ≥ 3 months;

          7. Pregnancy test (serum or urine) has to be performed for woman of childbearing age
             within 7 days before enrolment and the test result must be negative. They shall take
             appropriate methods for contraception during the study until the 8th week post the
             last administration of study drug. For men, (previous surgical sterilization
             accepted), shall agree to take appropriate methods of contraception during the study
             until the 8th week post the last administration of study drug;

          8. Patient has to voluntarily join the study and sign the Informed Consent Form for the
             study.

        Exclusion Criteria:

          1. Confirmed that apatinib and/or its accessories allergy;

          2. Subjects with poor-controlled arterial hypertension (systolic blood pressure&gt; 140 mmHg
             and diastolic blood pressure &gt; 90 mm Hg) despite standard medical management; Coronary
             heart disease greater than Class Ⅰ; Ⅰ-level arrhythmia (including QT interval
             prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class Ⅰ cardiac
             dysfunction; Patients with positive urinary protein;

          3. Factors that could have an effect on oral medication (such as inability to swallow,
             chronic diarrhea and intestinal obstruction);

          4. Subjects with high gastrointestinal bleeding risk, including the following conditions:
             local active ulcer lesions with positive fecal occult blood test (++); history of
             black stool, or vomiting blood in the past 2 months;unresected primary lesion in
             stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with
             massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy
             result;

          5. Abnormal Coagulation (INR&gt;1.5、APTT&gt;1.5 UNL), with tendency of bleed;

          6. Associated with CNS (central nervous system) metastases;

          7. Pregnant or lactating women;

          8. Pts with other malignant tumor within 5 years;

          9. With psychotropic drug abuse history and can't get rid of or mental disorder patients;

         10. Participated in other clinical trials within 4 weeks;

         11. Pts received VEGFR inhibitor treatment(i.e. sorafenib, sunitinib);

         12. Any other condition that might place the patient at undue risk or preclude a patient
             from completing the study;

         13. Other conditions regimented at investigators' discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Dai, Guanghai</investigator_full_name>
    <investigator_title>Department Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

